Cleveland BioLabs, Inc. (NASDAQ:CBLI) Files An 8-K Other Events
Item 8.01. Other Events.
Cleveland BioLabs Announces Commencement of In Vivo
Biocomparability Study and Cleveland BioLabs Announces European
Medicines Agency Positive Opinion Regarding the Entolimod
Pediatric Investigation Plan. A copy of each press release is
attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively,
and incorporated herein by reference.
|
Exhibit No.
|
Description
|
|
99.1
|
Press release of Cleveland BioLabs, Inc. dated April
17, 2017 |
|
99.2
|
Press release of Cleveland BioLabs, Inc. dated April
17, 2017 |
About Cleveland BioLabs, Inc. (NASDAQ:CBLI)
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5. Cleveland BioLabs, Inc. (NASDAQ:CBLI) Recent Trading Information
Cleveland BioLabs, Inc. (NASDAQ:CBLI) closed its last trading session up +3.17 at 4.80 with 38,456 shares trading hands.